Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Open access
Chen, Kang-Yin, Rha, Seung-Woon, Li, Yong-Jian, Poddar, Kanhaiya L., Jin, Zhe, Minami, Yoshiyasu, Wang, Lin, Kim, Eung Ju, Park, Chang Gyu, Seo, Hong Seog, Oh, Dong Joo, Jeong, Myung Ho, Ahn, Young Keun, Hong, Taek Jong, Kim, Young Jo, Hur, Seung Ho, Seong, In Whan, Chae, Jei Keon, Cho, Myeong Chan, Bae, Jang Ho, Choi, Dong Hoon, Jang, Yang Soo, Chae, In Ho, Kim, Chong Jin, Yoon, Jung Han, Chung, Wook Sung, Seung, Ki Bae, Park, Seung Jung · 2009 · Circulation

Abstract

Background— Whether triple antiplatelet therapy is superior or similar to dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in the era of drug-eluting stents remains unclear. Methods and Results— A total of 4203 ST-segment elevation myocardial infarction patients who underwent primary percutaneous coronary intervention with drug-eluting stents were analyzed retrospectively in the Korean Acute Myocardial Infarction Registry (KAMIR). They received either dual (aspirin plus clopidogrel; dual group; n=2569) or triple (aspirin plus clopidogrel plus cilostazol; triple group; n=1634) antiplatelet therapy. The triple group received additional cilostazol at least for 1 month. Various major adverse cardiac events at 8 months were compared between these 2 groups. Compared with the dual group, the triple group had a similar incidence of major bleeding events but a significantly lower incidence of in-hospital mortality. Clinical outcomes at 8 months showed that the triple group had significantly lower incidences of cardiac death (adjusted odds ratio, 0.52; 95% confidence interval, 0.32 to 0.84; P =0.007), total death (adjusted odds ratio, 0.60; 95% confidence interval, 0.41 to 0.89; P =0.010), and total major adverse cardiac events (adjusted odds ratio, 0.74; 95% confidence interval, 0.58 to 0.95; P =0.019) than the dual group. Subgroup analysis showed that older (>65 years old), female, and diabetic patients got more benefits from triple antiplatelet therapy than their counterparts who received dual antiplatelet therapy. Conclusions— Triple antiplatelet therapy seems to be superior to dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents. These results may provide the rationale for the use of triple antiplatelet therapy in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.108.822791

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 194

Metadata

Authors
Chen, K.-Y., Rha, S.-W., Li, Y.-J., Poddar, K. L., Jin, Z., Minami, Y., Wang, L., Kim, E. J., Park, C. G., Seo, H. S., Oh, D. J., Jeong, M. H., Ahn, Y. K., Hong, T. J., Kim, Y. J., Hur, S. H., Seong, I. W., Chae, J. K., Cho, M. C., Bae, J. H., Choi, D. H., Jang, Y. S., Chae, I. H., Kim, C. J., Yoon, J. H., Chung, W. S., Seung, K. B., & Park, S. J.
Venue
Circulation
Published
2009-06-30
Volume
119
Issue
25
Pages
3207-3214
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W1983980229
Cited by
194
References
1
FWCI
18.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. https://app.cochat.ai/papers/10.1161/circulationaha.108.822791
The paper
Chen, K.-Y., Rha, S.-W., Li, Y.-J., Poddar, K. L., Jin, Z., Minami, Y., Wang, L., Kim, E. J., Park, C. G., Seo, H. S., Oh, D. J., Jeong, M. H., Ahn, Y. K., Hong, T. J., Kim, Y. J., Hur, S. H., Seong, I. W., Chae, J. K., Cho, M. C., . . . Park, S. J. (2009). Triple Versus Dual Antiplatelet Therapy in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. https://doi.org/10.1161/circulationaha.108.822791

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.